Advance the Development of NK,
Gamma-Delta T, Macrophage, and NKT Cell Therapies to Develop Cost-Effective Treatments for Liquid and Solid Tumors

2021 has been a game-changing year for the NK cell community. Positive clinical results have forced the field to wake up to the potential of these pioneering approaches. 

Supporting the field since its’ infancy, the Innate Killer Summit returns for its 7th year as the leading, industry-defining forum dedicated to advancing the field to achieve clinical success.

Spanning the current drug development landscape, from improving gene editing transduction in discovery to cryopreservation and CMC in scaled manufacturing, this is the definitive meeting to focus on the clinical and scaled phase development of innate cell therapies.

Get your copy of the 2022 agenda here.

Join over 200 experts to characterize and contrast cell sources, supercharge combinations, optimize CMC workflows, examine expansion protocols for high-quality products at scale, and move the field towards persistent, scalable, and cost-effective innate immune cell therapies.

Promising unpublished data, interactive discussion, and engaging networking opportunities join the 7th Innate Killer Summit to forge new collaborations and capitalize on the clinical potential of innate immune cell therapies.

2022 Speakers Confirmed Include:

Anahid Jewett

Professor & Director Tumor Immunology Laboratory

UCLA

Michael DeRidder

VP Medicine Commercialization Leader, Oncology Cell Therapy

GSK

Thorsten Graef

CMO

Acepodia

Todd Fehniger

Professor of Medicine

Washington University School of Medicine, St. Louis

2022 Partners: